Drugs / Ethyl ascorbic acid
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07522788 Comparator | Jun → Nov 2026 expected | hyperpigmentation of the skin | Hayatabad Medical Complex | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ethyl ascorbic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07522788 ↗ |
| Known as | EAA | “The rationale of this study is to compare the efficacy with topical TXA versus topical Ethyl Ascorbic Acid (EAA ) for Melasma in terms of reduction in MASI scores.” NCT07522788 ↗ |
| Route | Topical | “The participants in this arm of study will only receive topical ethyl ascorbic acid once daily at night for 12 weeks” NCT07522788 ↗ |